Melanoma education for people with autoimmune conditions
Part of Bones, joints & muscles, Cancer, Digestive system, Immune system & allergy, Infections, Skin clinical trials.
This trial tests an educational tool to help people with melanoma and pre-existing autoimmune disease understand immune checkpoint inhibitor treatment. It aims to support you and your care team with information that can help you make decisions and feel more prepared.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of melanoma.
- You have a pre-existing autoimmune disease such as Crohn’s/ulcerative colitis, rheumatoid arthritis, lupus, psoriasis, or certain related arthritis conditions.
- Your autoimmune disease is being treated with approved medicines (for example steroids, methotrexate, or other immune-related medications).
- You are 18 years or older and your doctor recommends starting an immune checkpoint inhibitor, or you’ve already decided about starting one.
- You can do remote communication by email/internet or phone, and you can speak English or Spanish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
This trial looks at whether adding a program of exercise and nutrition changes can improve quality of life and treatment outcomes for people with melanoma who are starting immunotherapy. If you qualify, you would take part in a structured plan to see if these lifestyle changes help.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study looks at whether extra monitoring and faster referrals to specialists can help manage side effects from immunotherapy (a treatment that helps your immune system fight cancer). It may make treatment easier to handle.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This trial is testing a new way to predict which immunotherapy might work best for your cancer. It uses a sample of your tumor to look for personal markers, so your treatment can be tailored to you.
Hear when a new Ankylosing Spondylitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.